Liraglutide

Fat LossFDA-approved daily GLP-1 agonistEstablished

Also known as: Victoza, Saxenda, NN2211

Liraglutide (also called Victoza or Saxenda) is an FDA-approved daily GLP-1 agonist. Liraglutide is a GLP-1 analog with a single amino-acid substitution and a sixteen-carbon fatty acid attached through a glutamate spacer.

Calculate Dose

For research use only.

Key Facts

CAS
204656-20-2
Molecular Weight (MW)
3751.2 g/mol
Half-life
Approximately 13 hours
FDA status
Approved
Evidence level
FDA Approved
Human dose established
Yes
Administration Route
Subcutaneous
Frequency
Once daily, at any time of day, independent of meals
Last updated
Sep 6, 2026
Reviewed
Sep 5, 2026
Targets
GLP-1 receptor

Vendor price snapshot

Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
2
Listed offers
2
Price per mg
$7.00–$20.60/mg

Open calculator · Compare vendors

Research summary

FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes (Victoza, up to 1.8 mg) and chronic weight management (Saxenda, up to 3 mg).

Research evidence

  • Regulatory review (FDA label)2 reviewed sources
  • Controlled human trials1 reviewed source
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Liraglutide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Liraglutide dosage evidence

Liraglutide has an FDA-approved human dosage. For weight management as Saxenda it is escalated weekly from 0.6 mg to a 3 mg once-daily subcutaneous maintenance dose. Unlike the once-weekly GLP-1 agonists it is grouped with, liraglutide is dosed once daily, and generic versions are now approved alongside the originator products.

FDA Approved
Dosage evidence summary for Liraglutide
Human dosing establishedYes
Studied dose range0.6–3 mg once daily
RouteSubcutaneous
FrequencyOnce daily, at any time of day, independent of meals
Duration studiedContinuous; maintenance reached in week 5
Titration0.6 mg week 1, 1.2 mg week 2, 1.8 mg week 3, 2.4 mg week 4, then 3 mg from week 5.
Half-lifeApproximately 13 hours
Evidence levelFDA Approved
Last reviewed2026-09-05

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Liraglutide, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
FDA label — Saxenda, weight managementFDA-approved label · FDA prescribing informationAdults with obesity or overweight with a weight-related comorbidity, and patients aged 12+ over 60 kg with obesity3 mg maintenance, escalated weekly from 0.6 mgSubcutaneous, abdomen, thigh or upper armOnce dailyContinuous, alongside reduced calorie diet and increased activityChronic weight managementSAXENDA (liraglutide) injection — FDA prescribing information, DailyMed
FDA label — generic liraglutide injectionFDA-approved label · FDA prescribing information, genericPer the referenced listed drug's approved indicationsAs per the originator labellingSubcutaneousOnce daily—Same indications as the reference productLIRAGLUTIDE injection — FDA prescribing information (Meitheal Pharmaceuticals), DailyMed
NCT01117350 — phase 4, results postedClinical trial · Phase 4 randomised trial with posted resultsAdults with type 2 diabetes (n=978)Per trial protocolSubcutaneousOnce dailyPer trial protocolGlycaemic control versus insulin glargine after oral therapy failureNCT01117350 — Efficacy Assessment of Insulin Glargine Versus Liraglutide After Oral Agent Failure

Where sources disagree

  • Liraglutide has two distinct approved dose ceilings by indication: 3 mg once daily under the Saxenda label for weight management, and a lower ceiling under the type 2 diabetes labelling. Quoting a single maximum without naming the product and indication is not meaningful.
  • Liraglutide is dosed once daily, not once weekly. Dosing intuition carried over from semaglutide or tirzepatide does not transfer, and the escalation schedule runs in weekly steps of daily doses.
Liraglutide dosage in published studies and labels →

Handling & administration

Reconstitution Guide
Prefilled pen — no reconstitution
Injection Sites
AbdomenThigh
Timing Notes
Educational catalog only — not medical advice

Sequence & molecular data

Sequence and molecular data for Liraglutide
Molecular formulaC172H265N43O51
Molecular weight3751.2 g/mol
CAS number204656-20-2
Half-life~13 hours
AppearanceClear solution in prefilled pen
FormulationPrefilled Pen
PubChem CID16134956
FDA UNII839I73S42A
ChEMBLCHEMBL4084119

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Liraglutide is a GLP-1 analog with a single amino-acid substitution and a sixteen-carbon fatty acid attached through a glutamate spacer. The acyl chain drives reversible binding to serum albumin and promotes self-association at the injection site, which together slow absorption and clearance and extend the half-life from minutes to roughly thirteen hours, allowing once-daily administration. At the GLP-1 receptor it enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, and slows gastric emptying. Appetite reduction is mediated centrally, through GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, which is why the weight effect is separate from the glycaemic one.

Origin

Acylated human GLP-1 analog (Novo Nordisk).

Targets

GLP-1 receptor

Research statistics

4,873 PubMed publications · 35.9% human clinical research · 457 registered trials

Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Liraglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Liraglutide
FDA statusApproved
AvailabilityPrescription-Only
WADA (sport)Permitted
Library classificationFDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

Labeled T2D and obesity therapyCV outcome data (Victoza)

Liraglutide side effects

The effects below are drawn from Liraglutide's prescribing information, which lists the full adverse-reaction data.

Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Gallbladder events

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Liraglutide: frequently asked questions

What is Liraglutide?

FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes (Victoza, up to 1.8 mg) and chronic weight management (Saxenda, up to 3 mg).

How does Liraglutide work?

Liraglutide is a GLP-1 analog with a single amino-acid substitution and a sixteen-carbon fatty acid attached through a glutamate spacer. The acyl chain drives reversible binding to serum albumin and promotes self-association at the injection site, which together slow absorption and clearance and extend the half-life from minutes to roughly thirteen hours, allowing once-daily administration.

Is Liraglutide FDA approved?

Yes. Liraglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What is the half-life of Liraglutide?

Reported half-life for Liraglutide is ~13 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

Is Liraglutide banned in sport?

Liraglutide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

What peptides are similar to Liraglutide?

Compounds most often compared with Liraglutide include Semaglutide, Tirzepatide, Retatrutide and Exenatide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 2

This Liraglutide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Liraglutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →